Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Obinutuzumab in the Management of Idiopathic Membranous Nephropathy

NCT05845762 is registered in ClinicalTrials.gov with Qianfoshan Hospital as lead sponsor.

NCT NCT05845762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05845762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Obinutuzumab in the Management of Idiopathic Membranous Nephropathy
Lead sponsor
Qianfoshan Hospital
Phase
Observational
Overall status
Unknown status
Start date
July 31, 2023
Completion date
December 31, 2023
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic membranous nephropathy